To determine the genetic etiology of the severe early infantile onset syndrome of malignant migrating partial seizures of infancy (MPSI).
have been identified in Dravet-like girls. Mutations in the cyclin-dependent kinase-like protein type 5 (CDKL5) gene cause a severe EE with early onset tonic seizures and spasms, mainly in girls. Mutations in the mitochondrial DNA polymerase ␥ type 1 (POLG) gene include encephalopathy and early-onset epilepsy. Ohtahara syndrome and early onset EE are associated with syntaxin binding protein 1 (STXBP1) mutations. 5 We screened children with MPSI for mutations in SCN1A, CDKL5, STXBP1, PCDH19 (females only), and the 3 common European mutations of POLG. Where possible, array CGH was performed to identify pathogenic copy number variations (CNV).
Here, we implicate SCN1A as causative in some patients with MPSI.
METHODS Clinical methods. Fifteen patients with
MPSI were referred from Australia, Sweden, Canada, and the United States. The MPSI phenotype was diagnosed according to the following criteria: onset under 6 months; presentation with focal or hemiclonic seizures, with progression to frequent, almost continuous, multifocal seizures; developmental arrest at seizure onset and progressive cognitive decline with clusters of seizures; and no etiology identified despite extensive investigation.
Molecular screening. Genomic DNA was extracted from peripheral blood leukocytes. SCN1A and CDKL5 mutations were screened by denaturing high-pressure liquid chromatography and characterized by direct sequencing as previously published. 4, 6 SCN1A MLPA testing was also performed for negative cases. Three common POLG mutations of ancient European origin (p.W748S, p.A467T, and p.G848S) were analyzed using a standard multiplex single nucleotide polymerase extension reaction method. 7 STXBP1 was sequenced for point mutations and multiplex amplicon quantification performed for CNV as previously described. 5 Microarray analysis was performed using commercially available exon-focused oligonucleotide arrays with either 105,000 (1 patient) or 720,000 (11 patients) probes.
Standard protocol approvals, registrations, and patient consents. The Austin Health Human Research Ethics
Committee approved this study. Informed consent was obtained from the parents or guardians of patients.
RESULTS
The clinical and molecular details of 15 patients with MPSI are presented in table 1 and table e-1 and appendix e-1 on the Neurology ® Web site at www.neurology.org. Two patients had pathogenic de novo changes involving the SCN1A gene. No mutations were found in CDKL5 (13 cases), STXBP1 (13 cases), or PCDH19 (9 females). The 3 most common European autosomal recessive mutations of POLG were not found in 11 patients tested. Of 12 patients tested for CNV, one had a large pathogenic deletion of chromosome Nineteen patients with variable deletions of chromosome 2(q24-q31) have been reported, including 12 with epilepsy. 8 While the epilepsy syndromes were generally mixed, one boy with a chromosome 2q24.3q31.1 10.4 Mb deletion shared some features with MPSI but the authors concluded that he did not fulfill the criteria. 9 He had dysmorphic features and multiple seizure types including spasms and atonic seizures. Since one of the SCN1A mutations that we report is a missense mutation, this suggests that adjacent genes within the microdeletion of the other case are not necessarily involved in producing MPSI. However, modifier genes or genetic background may be responsible for the more severe phenotype in these cases with MPSI than the similar missense mutation and microdeletions that cause Dravet syndrome.
SCN1A mutations are associated with a spectrum of epilepsies, which vary markedly in severity from severe infantile epileptic encephalopathies to benign febrile seizures in genetic epilepsy with febrile seizures plus. The most severe SCN1A phenotype until now has been Dravet syndrome, which is less severe than MPSI and has a later onset age, normal early development, different seizure semiology, and evolution. de Novo SCN1A mutations are found in 70% of patients with Dravet syndrome. 4 MPSI bears more resemblance to the SCN1A EE of SIMFE, as they share an electroclinical pattern of refractory multifo-cal seizures, but patients with SIMFE have early normal development prior to later regression and a better outcome than MPSI. 4 Our 2 cases extend the most severe end of the phenotypic spectrum of SCN1A epilepsies to include MPSI.
Previous genetic investigation of MPSI in 3 patients did not reveal mutations in SCN1A, SCN2A, KCNQ2, KCNQ3, and CLCN2. 10 CNV within SCN1A was also excluded in our cases. However, SCN1A mutations explain only 2/15 (13%) of our cases, suggesting that genetic heterogeneity underlies MPSI. Although the numbers examined in MPSI remain relatively small, our findings fail to support a role for CDKL5, STXBP1, PCDH19, and POLG, but indicate that a proportion of MPSI may have pathogenic CNV.
More than 60 cases of MPSI have been published over 15 years. Increased awareness of this underrecognized syndrome and advances in molecular technology will facilitate the discovery of genetic causes that in turn will inform the neurobiology of this devastating disorder. Furthermore, genetic screening facilitates early diagnosis and avoids the burden of multiple investigations such as liver and muscle biopsies and epilepsy surgery evaluation in children with severe early-onset epilepsies. Thus early genetic screening is cost-effective in patients with MPSI and may help guide management and genetic counseling. In particular, the revolution in molecular karyotyping has been associated with an increasing yield in terms of etiologic diagnosis, is becoming less expensive, and is now a first-tier diagnostic test in severe epilepsies and mental retardation. Now, SCN1A screening should be considered in patients with MPSI as one of the genetic etiologies of this devastating epileptic encephalopathy. Epilepsy Society, the Jack Brockhoff Foundation, the Shepherd Foundation, and the Perpetual Charitable Trustees.
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